Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516502 | 1.00 | CYP4F2 (0.45) | CYP4F2CYP4A11TP53DRD3LMNA | |
| SCHEMBL24229002 | 1.00 | CYP4F2 (0.45) | CYP4F2CYP4A11TP53DRD3LMNA | |
| SCHEMBL29516709 | 1.00 | CYP4F2 (0.45) | CYP4F2CYP4A11TP53DRD3LMNA | |
| SCHEMBL24228942 | 1.00 | CYP4F2 (0.45) | CYP4F2CYP4A11TP53DRD3LMNA | |
| SCHEMBL545604 | 1.00 | CYP4F2 (0.45) | CYP4F2CYP4A11TP53DRD3LMNA | |
| SCHEMBL537418 | 0.86 | ROCK2 (0.51) | CYP4F2CYP4A11TP53LMNAMAOB | |
| SCHEMBL1519508 | 0.83 | ROCK2 (0.51) | CYP4F2CYP4A11TP53LMNAROCK2 | |
| SCHEMBL1519430 | 0.83 | MALT1 (0.42) | CYP4F2CYP4A11TP53LMNAMAOB | |
| SCHEMBL1519562 | 0.83 | ROCK2 (0.51) | CYP4F2CYP4A11TP53LMNAMAOB | |
| SCHEMBL27927241 | 0.83 | TDP1 (0.55) | CYP4F2CYP4A11TP53LMNAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| CN-116601150-A | Fused bicyclic RAF inhibitors and methods of use thereof | 爵士制药爱尔兰有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-RE49361-E1 | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-01-10 | — | — | US | disclosed |
| CN-114921508-B | Biocatalytic preparation method of (R) -6-hydroxy chroman-3-carboxylic acid | 常熟药明康德新药开发有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114921508-A | Biocatalytic preparation method of (R) -6-hydroxy chroman-3-carboxylic acid | 常熟药明康德新药开发有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022023450-A1 | CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022023447-A2 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-02-03 | — | — | WO | disclosed |
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-02-03 | — | — | US | disclosed |
| CN-107108588-B | Fused bicyclic (hetero) aromatic compounds useful for the treatment of cancer | 杰资制药爱尔兰有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10183939-B2 | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | REDX PHARMA PLC (GB) | 2019-01-22 | — | — | US | disclosed |
| EP-3191477-B1 | FUSED BICYCLIC (HETERO)AROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS | REDX PHARMA PLC (GB) | 2018-07-18 | — | — | EP | disclosed |
| US-20170298061-A1 | FUSED BICYCLIC (HETERO)AROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS | U.S. BANK NATIONAL ASSOCIATION | 2017-10-19 | — | — | US | disclosed |
| US-20170298061-A1 | FUSED BICYCLIC (HETERO)AROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS | U.S. BANK NATIONAL ASSOCIATION | 2017-10-19 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| CN-101365682-A | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARM INC (US) | 2009-02-11 | — | — | CN | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298061-A1 | FUSED BICYCLIC (HETERO)AROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS | BRAF, ARAF, RAF1 | CYP4F2 887/4885CYP4A11 2092/4885TP53 121/4885 |
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, RAF1, NRAS | CYP4F2 1094/4885CYP4A11 1168/4885TP53 114/4885 |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | CYP4F2 1094/4885CYP4A11 1168/4885TP53 114/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | CYP4F2 3792/4885CYP4A11 2207/4885TP53 1008/4885 |
| US-10183939-B2 | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | BRAF, ARAF, RAF1 | CYP4F2 887/4885CYP4A11 2092/4885TP53 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.